Friday, Dec 1, 2023 · SEC filings
What the smart money revealed on Dec 1
588 insider filings came in. We hid 86 planned (10b5-1) sellers and 298 people whose filings were routine, like grants and tax withholding.
Anterix (ATEX) Director Jeffrey Altman bought $4.07M
124,192 shares on the open market. Not a grant or an option exercise.
Pulse Biosciences (PLSE) Director Robert Duggan bought $2.05M
218,600 shares on the open market. Not a grant or an option exercise. Their past buys: 1 of 6 checked quarters beat the typical stock 6 months later.
Sight Sciences (SGHT) Director Staffan Encrantz bought $498K
144,000 shares on the open market. Not a grant or an option exercise. Their past buys: 3 of 4 checked quarters beat the typical stock 6 months later.
Y-mAbs Therapeutics (YMAB) Director Johan Wedell-Wedellsborg bought $309K
51,837 shares on the open market. Not a grant or an option exercise.
Medpace (MEDP) CEO August Troendle sold $14.5M
Not marked as a planned 10b5-1 sale. Sold 1% of the shares they held directly. Still holds 5.59M shares.
Confluent (CFLT) Director Michelangelo Volpi sold $6.73M
Not marked as a planned 10b5-1 sale. Most of the shares sold came from stock options they exercised the same day. Still holds 14,948 shares directly.
P10 (RPC) Director Edwin Poston sold $180K
Not marked as a planned 10b5-1 sale. Sold every share held directly.
Show 38 more real buys
Show 107 more real sales
13F season
Holdings as of Sep 30, 2023 were due Nov 14
40 funds have filed. 40 filed for the quarter before.
Biggest real insider buys, Nov 25–Dec 1
Open-market buys by officers and directors, filed in the 7 days up to Dec 1.
Free weekly email
Each week's biggest real insider buys, cluster buys and fund moves, every one dated. One email a week. Unsubscribe in one click.